Evercore ISI lowered the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $649 from $652 and keeps an Outperform rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- Madrigal Pharmaceuticals reports Q1 EPS ($3.25), consensus ($4.14)
- Madrigal Earnings Call: Rezdiffra Boom, Profits Delayed
- Madrigal Pharmaceuticals price target raised to $680 from $533 at Clear Street
- Arrowhead announces exclusive worldwide license agreement with Madrigal Pharma
- MDGL Earnings Report this Week: Is It a Buy, Ahead of Earnings?